OakChart

RenovoRx Inc

RNXTHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 1:37 PM ET

1.25+0.07 (5.93%)
2026-11-11 19:41 CET
Market cap
56.94 USD m
Revenue, TTM
2.78 USD m
Net income, TTM
-13.02 USD m
Free cash flow, TTM
-12.22 USD m
EPS diluted, TTM
-0.31
P/E
-
Compare

Price

RNXT against its 20, 50 and 200-day averages
2050200earnings
1.001.502.002.502.1M4.1MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26RNXTclose 1.2520-day 1.2650-day 1.50200-day 1.111.2552w high52w low

51.7% under the 52-week high of 2.59 on 2 Sep 2026. 52-week low 0.70 on 14 Nov 2025. Last 15 sessions, 76.1% high to low

Profile

RNXT
52-week range, 29% of the way up
0.702.59

RenovoRx, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a therapy platform to deliver chemotherapy. Its therapy platform includes RenovoTAMP, a therapy platform designed for targeted delivery of chemotherapy enabling localized treatment of solid tumors. The company was founded by Ramtin Agah and Kamran Najmabadi in 2009 and is headquartered in Mountain View, CA.

Employees17
IPOAug 26, 2021
Beta1.19
ATR, 14d0.15
Rel volume0.28
Short float2.15%
Insider own3.66%
Inst own19.10%

Snapshot

6 groups

Valuation

Index-
Market Cap60.32M
Enterprise Value50.28M
Income-13.02M
Sales2.78M
Book/sh0.19
Cash/sh0.22
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees17
IPOAug 26, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S21.70
P/B6.49
P/C5.80
P/FCF-
EV/EBITDA-
EV/Sales18.09
Quick Ratio5.49
Current Ratio5.65
Debt/Eq0.04
LT Debt/Eq0.02
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.31
EPS next Y-0.10
EPS next Q-0.06
EPS this Y17.97%
EPS next Y60.95%
EPS next 5Y-
EPS past 3/5Y33.86% 6.34%
Sales past 3/5Y- -
EPS Y/Y TTM12.75%
Sales Y/Y TTM199.14%
EPS Q/Q4.78%
Sales Q/Q300.75%
EarningsNov 05 AMC
EPS/Sales Surpr.-33.33% 0.14%

Ownership

Insider Own3.66%
Insider Trans1.44%
Inst Own19.10%
Inst Trans0.14%
ROA-110.14%
ROE-149.98%
ROIC-136.92%
Gross Margin84.04%
Oper. Margin-489.05%
Profit Margin-469.02%
SMA20-0.85%
SMA50-16.79%
SMA20012.43%
Trades-

Technical

Shs Outstand48.19M
Shs Float46.48M
Short Float2.15%
Short Ratio1.21
Short Interest1.00M
52W High2.59 -51.74%
52W Low0.70 78.42%
Volatility22.95% 11.48%
ATR (14)0.15
RSI (14)46.22
Beta1.19
Rel Volume0.28
Avg Volume821.90K
Volume153,719

Performance

Perf Week-4.58%
Perf Month8.70%
Perf Quarter-0.79%
Perf Half Y47.30%
Perf YTD48.79%
Perf Year16.82%
Perf 3Y15.74%
Perf 5Y-85.29%
Perf 10Y-
Recom1.00
Target Price7.12
Prev Close1.18
Price1.25
Change %5.93%

Peers

Mkt cap
TickerCompanyMkt cap
ONCYOncolytics Biotech Inc49.75M
ELTXElicio Therapeutics Inc43.87M
DRTSAlpha Tau Medical Ltd1.33B
NBTXNanobiotix ADR1.68B
OBIOOrchestra BioMed Holdings Inc371.01M
PMCBPharmaCyte Biotech Inc4.28M
PPCBPropanc Biopharma Inc1.94M
SLXNSilexion Therapeutics Corp1.95M
IMNNImunon Inc4.29M
PCSAProcessa Pharmaceuticals Inc5.13M

Insider trading

10 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
VOLL MARKChief Financial OfficerMay 19 '26Buy0.7925,00019,690142,380May 21 07:00 AM
Agah RamtinChief Medical OfficerJan 21 '26Buy1.0010,0009,975798,460Jan 22 07:00 AM
Agah RamtinChief Medical OfficerDec 31 '25Buy0.869,7958,424788,460Jan 05 07:00 AM
Agah RamtinChief Medical OfficerDec 30 '25Buy0.83205169778,665Jan 02 05:00 PM
Bagai ShaunChief Executive OfficerDec 18 '25Buy0.905,0004,506340,040Dec 22 07:00 AM
Bagai ShaunChief Executive OfficerDec 17 '25Buy0.855,0004,262335,040Dec 19 07:00 AM
Agah RamtinChief Medical OfficerDec 16 '25Buy0.8512,00010,200778,460Dec 17 07:00 AM
Agah RamtinChief Medical OfficerDec 05 '25Buy0.9610,0009,600766,460Dec 08 07:00 AM
Agah RamtinChief Medical OfficerNov 24 '25Buy0.8012,0009,600756,460Nov 24 06:00 PM
Agah RamtinChief Medical OfficerNov 21 '25Buy0.8010,0008,000744,460Nov 24 06:00 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200
  • RenovoRx Posts First $1 Million Quarter And Misses On EPS As Sequential Growth Slows And Q4 Targets Get Harder (Earnings Whispers) -9.16% -5.04%
  • RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million (GlobeNewswire)
  • RenovoRx Must Show Center Growth Can Turn A Raised Guide Into Another Record (Earnings Whispers)
  • RenovoRx to Participate at the Canaccord Genuity MedTech Diagnostics and Digital Health & Services Forum (GlobeNewswire)
  • RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026 (GlobeNewswire)
  • RenovoRx Advances TAMP into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial (GlobeNewswire)
  • RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer (GlobeNewswire)
  • RenovoRx H.C. Wainwright Presentation to Highlight RenovoCath Growth and Phase III TIGeR-PaC Timeline (InvestorsHub) +19.43%
  • RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th (GlobeNewswire)
  • RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP Platform's Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer (GlobeNewswire) +13.60%
  • RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
  • RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment (GlobeNewswire)
  • RenovoRx Inc (RNXT) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic Expansion ... (GuruFocus.com) +12.50%
  • RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.080-0.060-0.0901.071.064
2026Q22026-08-12-0.060-0.073-0.0620.910.704
2026Q12026-05-14-0.090-0.080-0.0930.560.474
2025Q42026-03-30-0.080-0.080-0.0800.240.424
2025Q32025-11-13-0.080-0.080-0.0800.270.414
2025Q22025-08-14-0.080-0.085-0.0790.420.334
2025Q12025-05-15-0.080-0.080-0.0770.200.183
2024Q42025-04-01-0.117-0.110-0.1200.040.004
2024Q32024-11-14-0.100-0.117-0.0990.000.003
2024Q22024-08-14-0.100-0.105-0.0990.000.002
2024Q12024-05-13-0.070-0.130-0.0720.00-1
2023Q42024-03-27-0.305-0.305-0.302-0.002
2023Q32023-11-14-0.130-0.280-0.1330.000.002
2023Q22023-08-17-0.220-0.290-0.2180.000.002
2023Q12023-05-15-0.360-0.250-0.3580.000.002
2022Q42023-03-02-0.240-0.260-0.2370.000.002

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-1.210-1.240-0.7080.000.00
2022FY-1.090-1.115-1.0930.000.00
2023FY-0.990-1.005-0.9940.00-
2024FY-0.400-0.390-0.3960.040.00
2025FY-0.320-0.318-0.4001.121.30
2026FY--0.263--3.85
2027FY--0.103--10.58
2028FY-0.000--33.53
2029FY-0.563--118.45
2030FY-1.553--254.25

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-104211.341.201.50
2026Q4S2026-11-094311.341.201.50
2026Q4S2026-11-064211.341.201.50
2026Q4S2026-11-014101.341.201.44
2026Q4S2026-10-274201.341.201.44
2026Q4S2026-08-274401.341.201.44
2026Q4S2026-08-184301.311.101.44
2026Q4S2026-08-134201.301.101.44
2026Q4S2026-08-124001.131.081.23
2026Q4S2026-07-294011.131.081.23
2026Q4S2026-05-294031.131.081.23
2026Q4S2026-05-154031.171.081.25
2026Q4S2026-04-074121.251.101.54
2026Q4S2026-03-313101.381.101.54

Estimate history

EPS, annual-0.443-0.439-0.708-1.093-0.994-0.396-0.316-0.3101
Period2019202020212022202320242025TTM
EPS, quarterly-0.099-0.12-0.077-0.079-0.08-0.08-0.093-0.062-0.076
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual000000.0431.1232.78
Period2019202020212022202320242025TTM
Sales, quarterly00.0430.1970.4220.2660.2380.5630.9091.066
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual8.6628.6628.9349.09810.69424.03536.61448.19
Period2019202020212022202320242025MRQ
Shares, quarterly24.00124.03536.54736.64636.6536.61445.05345.12248.19
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue2.781.120.040.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.440.33-0.000.010.010.000.00
Gross Profit2.330.80-0.00-0.01-0.010.000.00
Selling, General and Administrative Excl. Other15.9113.3111.0111.409.945.663.203.90
Research and Development5.176.276.035.674.303.042.393.00
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-13.58-12.51-10.97-11.40-9.95-5.67-3.20-3.90
Interest Expense0.000.000.000.000.000.900.59-
Unusual Expense-0.27-0.92-1.77-1.060.000.060.000.01
Net Income Before Taxes-13.02-11.17-8.81-10.23-9.89-6.32-3.80-3.84
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-13.02-11.17-8.81-10.23-9.89-6.32-3.80-3.84
Net Income From Continuing Operations-13.02-11.17-8.81-10.23-9.89-6.32-3.80-3.84
Net Income-13.02-11.17-8.81-10.23-9.89-6.32-3.80-3.84
EPS (Recurring)-0.27-0.33-0.45-1.07-1.09-0.70-0.44-0.44
EPS (Basic, Before Extraordinaries)-0.31-0.32-0.40-0.99-1.09-0.71-0.44-0.44
EPS (Diluted)-0.31-0.32-0.40-0.99-1.09-0.71-0.44-0.44
EBITDA-13.56-12.51-10.97-11.40-9.94-5.66-3.20-3.90
Non-Operating Income (Expense)0.280.430.380.110.060.31-0.000.07
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.641.271.171.080.640.150.030.04
Price To Sales Ratio27.0826.43668.13-----
Gross Margin84.0470.88------
Operating Margin-489.05-1,113.98-25,511.63-----
Net Margin-469.02-994.48-20,497.67-----
Shares Outstanding48.1936.6124.0310.699.108.938.668.66
Market Capitalization56.9456.9430.9624.4921.3843.1244.10-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue1.070.910.560.240.270.420.200.04
Cost of Goods Sold Incl. D&A0.190.140.080.030.050.150.09-
Gross Profit0.880.770.480.210.210.270.10-
Selling, General and Administrative Excl. Other4.114.123.953.733.412.953.212.67
Research and Development1.241.201.231.501.691.431.641.58
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-3.24-3.35-3.47-3.52-3.20-2.68-3.11-2.63
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.49-0.350.10-0.51-0.170.35-0.580.33
Net Income Before Taxes-3.65-2.91-3.52-2.94-2.91-2.90-2.42-2.88
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-3.65-2.91-3.52-2.94-2.91-2.90-2.42-2.88
Net Income From Continuing Operations-3.65-2.91-3.52-2.94-2.91-2.90-2.42-2.88
Net Income-3.65-2.91-3.52-2.94-2.91-2.90-2.42-2.88
EPS (Recurring)-0.07-0.07-0.09-0.09-0.08-0.07-0.09-0.11
EPS (Basic, Before Extraordinaries)-0.08-0.06-0.09-0.08-0.08-0.08-0.08-0.12
EPS (Diluted)-0.08-0.06-0.09-0.08-0.08-0.08-0.08-0.12
EBITDA-3.23-3.34-3.47-3.52-3.20-2.68-3.11-2.63
Non-Operating Income (Expense)0.080.090.040.070.110.130.110.09
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.470.570.320.280.350.340.290.25
Price To Sales Ratio27.0823.4625.8027.4050.1572.66129.51721.04
Gross Margin82.3684.2785.0888.2480.0863.9852.28-
Operating Margin-303.56-368.43-616.16-1,479.83-1,203.01-634.60-1,578.68-6,120.93
Net Margin-342.12-320.24-625.40-1,235.71-1,094.74-686.02-1,228.43-6,693.02
Shares Outstanding48.1945.1245.0536.6136.6536.6536.5524.03
Market Capitalization56.9444.1537.0230.7946.5448.0935.2130.96

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments7.027.151.176.4415.191.792.12
Short Term Receivables0.140.040.000.000.000.000.00
Inventories0.190.000.000.000.000.000.00
Other Current Assets0.540.630.190.821.090.120.14
Total Current Assets7.897.831.367.2616.281.912.27
Net Property, Plant & Equipment0.200.290.000.000.010.000.00
Total Investments and Advances0.000.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.00--
Deferred Tax Assets0.050.08-----
Other Assets0.000.000.100.000.000.000.00
Total Assets8.148.201.477.2616.291.912.27
Short Term Debt Incl. Current Port. of LT Debt0.100.070.000.000.002.770.00
Accounts Payable0.800.590.560.530.530.160.54
Other Current Liabilities1.061.263.900.570.411.170.27
Total Current Liabilities1.961.914.471.100.944.100.81
Long Term Debt0.110.210.000.000.0012.4712.39
Provision for Risks Charges0.000.000.000.000.000.000.00
Deferred Tax Liabilities0.050.08-----
Other Liabilities0.601.520.000.000.000.000.00
Total Liabilities2.723.724.471.100.9416.5713.20
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00
Common Equity5.424.48-3.006.1615.35-14.66-10.93
Total Shareholders Equity5.424.48-3.006.1615.35-14.66-10.93
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity5.424.48-3.006.1615.35-14.66-10.93
Total Liabilities & Stockholders Equity8.148.201.477.2616.291.912.27
Book Value Per Share0.150.19-0.280.681.72-1.69-1.26
Tangible Book Value Per Share0.150.19-0.280.681.72-1.69-1.26
Full-Time Employees1710896--
Price to Book Ratio6.134.384,089.292.622.822.51-
Return on Assets-136.69-182.43-234.38-83.98-69.49-181.55-
Return on Equity-225.62-1,192.69-646.98-91.94-1,825.11--
Return on Invested Capital-201.99-187.93--160.46-41.20--262.05
Quick Ratio3.934.100.316.5917.360.472.81
Current Ratio4.024.100.316.5917.360.472.81

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-13.02-11.17-8.81-10.23-9.89-6.32-3.80-3.84
Depreciation0.010.00-0.000.010.01--
Other Funds (Non Cash)1.480.44-0.59-0.630.640.660.540.05
Funds from Operations-11.52-10.73-9.40-10.86-9.24-5.65-3.26-3.79
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-0.61-0.250.280.600.43-0.27-0.270.44
Cash from Operating Activities-12.13-10.97-9.12-10.26-8.81-5.92-3.53-3.35
Capital Expenditures-0.09-0.00-0.010.000.00-0.010.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.002.03-2.030.000.000.00
Purchase of Investments0.000.000.000.00-8.000.000.000.00
Sale Or Maturity of Investments0.000.000.002.035.970.000.000.00
Other Uses0.000.000.000.000.000.000.00-0.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.09-0.00-0.012.03-2.03-0.010.00-0.00
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock12.5910.8515.125.010.0417.350.040.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock12.5910.8515.125.010.0417.350.040.00
Proceedsfrom Stock Options9.1010.800.005.000.0014.560.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.001.983.160.00
Change in Long Term Debt0.000.000.000.000.000.000.120.00
Issuance of Long Term Debt0.000.000.000.000.000.000.120.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.00
Cash from Financing Activities12.5910.8515.125.010.0419.333.200.00
Net Change in Cash0.36-0.135.98-3.22-10.8013.40-0.33-3.35
Free Cash Flow-12.22-10.97-9.14-10.26-8.81-5.93-3.53-3.35
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments10.409.4812.367.0210.0412.31
Short Term Receivables0.610.480.280.140.170.36
Inventories0.340.380.380.190.270.00
Other Current Assets0.460.470.700.540.490.72
Total Current Assets11.8110.8113.727.8910.9813.39
Net Property, Plant & Equipment0.420.460.240.200.230.25
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets--0.000.000.000.00
Deferred Tax Assets---0.05--
Other Assets0.200.200.000.000.000.00
Total Assets12.4411.4713.968.1411.2113.64
Short Term Debt Incl. Current Port. of LT Debt0.130.130.110.100.100.10
Accounts Payable0.940.871.120.800.870.67
Other Current Liabilities1.020.890.691.060.910.79
Total Current Liabilities2.091.881.921.961.881.56
Long Term Debt0.230.260.080.110.130.16
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---0.05--
Other Liabilities0.840.350.700.601.111.28
Total Liabilities3.152.492.702.723.133.00
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity9.288.9811.275.428.0810.64
Total Shareholders Equity9.288.9811.275.428.0810.64
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity9.288.9811.275.428.0810.64
Total Liabilities & Stockholders Equity12.4411.4713.968.1411.2113.64
Book Value Per Share0.190.200.250.150.220.29
Tangible Book Value Per Share0.190.200.250.150.220.29
Full-Time Employees---17--
Price to Book Ratio6.133.926.823.814.373.65
Return on Assets-110.14-97.83-81.85-136.69-104.58-83.16
Return on Equity-149.98-125.23-100.47-225.62-146.61-107.11
Return on Invested Capital-38.35-31.51-31.04-53.19-35.46-26.80
Quick Ratio5.495.536.953.935.688.61
Current Ratio5.655.747.154.025.838.61

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-3.65-2.91-3.52-2.94-2.91-2.90
Depreciation0.010.010.000.00-0.000.00
Other Funds (Non Cash)0.990.260.44-0.200.200.71
Funds from Operations-2.65-2.65-3.08-3.14-2.72-2.18
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.11-0.22-0.630.120.45-0.12
Cash from Operating Activities-2.54-2.87-3.71-3.02-2.27-2.30
Capital Expenditures-0.02-0.070.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.02-0.070.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock3.480.069.050.000.000.03
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock3.480.069.050.000.000.03
Proceedsfrom Stock Options0.000.069.050.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities3.480.069.050.000.000.03
Net Change in Cash0.93-2.885.34-3.02-2.27-2.27
Free Cash Flow-2.56-2.94-3.71-3.02-2.27-2.30

Revenue breakdown

Surgical & Medical Instruments & Apparatus2024: 43.00K 2025: 1.12M
United States2024: 43.00K 2025: 1.12M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-302.15%1.0M46.5M804.95K
2026-10-151.99%0.9M43.5M789.41K
2026-09-302.18%0.9M43.5M740.57K
2026-09-151.55%0.7M43.5M686.36K
2026-08-310.99%0.4M43.6M404.42K
2026-08-141.55%0.7M43.6M311.34K
2026-07-310.65%0.3M43.5M259.20K
2026-07-150.75%0.3M43.5M280.15K
2026-06-300.80%0.3M43.5M302.12K
2026-06-150.80%0.3M43.5M369.84K
2026-05-290.96%0.4M43.5M370.77K
2026-05-150.88%0.4M43.5M345.24K
2026-04-301.17%0.5M43.2M330.50K
2026-04-151.09%0.5M43.2M316.75K
2026-03-311.37%0.6M43.5M346.96K
2026-03-131.75%0.6M35.4M260.13K
2026-02-271.23%0.4M35.4M239.41K
2026-02-131.26%0.4M35.4M277.24K
2026-01-301.58%0.6M35.4M305.96K
2026-01-151.53%0.5M35.4M322.52K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-06SCHEDULE 13G/ASEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-16RWRegistration Withdrawal RequestSEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-10SEC
2026-08-208-KCurrent report2026-08-20SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-K/A2026-08-12SEC
2026-08-128-KCurrent report2026-08-12SEC
2026-08-048-KCurrent report2026-08-04SEC
2026-07-028-KCurrent report2026-07-01SEC
2026-06-30S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-06-308-KCurrent report2026-06-30SEC
2026-06-244Statement of changes in beneficial ownership of securities2022-03-03SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-05-1510-K/A2025-12-31SEC
2026-05-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-148-KCurrent report2026-05-14SEC
2026-04-30DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-04-30SEC
2026-04-27EFFECTEffectiveness filing by commission orderSEC
2026-04-27424B3SEC
2026-04-27SCHEDULE 13G/ASEC
2026-04-23CORRESPSEC
2026-04-22UPLOADUpload SubmissionSEC
2026-04-16S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-04-09DNotice of sales of securities on Form D (Regulation D)SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-0519.69K100
2026-040000
2026-030000
2026-020000
2026-019.98K100
2025-1237.16K600
2025-1117.60K200

Institutional holders

Manager% owned
AIGH Capital Management LLC9.45%
Bleichroeder LP3.70%
VANGUARD CAPITAL MANAGEMENT LLC3.20%
GEODE CAPITAL MANAGEMENT, LLC1.05%
Wealthspire Advisors, LLC0.56%
VANGUARD FIDUCIARY TRUST CO0.53%
SEI INVESTMENTS CO0.36%
CITADEL ADVISORS LLC0.30%
T3 Companies, LLC0.21%
Chicago Partners Investment Group LLC0.20%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.30%
VANGUARD EXTENDED MARKET INDEX FUND0.84%
Fidelity Extended Market Index Fund0.45%
Fidelity Total Market Index Fund0.17%
Fidelity Series Total Market Index Fund0.14%
Fidelity Nasdaq Composite Index Fund0.08%
VANGUARD BALANCED INDEX FUND0.07%

OakChart. RNXT. Cached 15 minutes.

Some panels did not load: ratings.